Anti-VEGF treatment in ROP: 11 Years of Experience


Anti-VEGF treatment in ROP 11 Years of Experience by Susana Teixeira, Rosalina Barroso, Graca Pires, Mafalda Mota, Filomena Silva, Portugal


ROP remains one of the leading causes of preventable childhood blindness worldwide. The ablative treatment strategy has been used for more than 30 years now and it’s efficacy and limitations are well known. In 2006, we began to use anti-VEGF (avastin) intravitreal injection for the treatment of type 1 ROP aiming to use an angiomodulation strategy in the treatment of ROP. The authors present their 11-year experience with intravitreal anti-VEGF injection in type1 ROP. We injected 93 eyes of 56 infants with type 1 ROP, 11 eyes (7 infants) as a combined treatment when lasertherapy failed and 82 eyes (45 infants) as a primary treatment. Twenty-six eyes had aggressive posterior ROP (AP-ROP), 52 eyes had Zone 1 / posterior zone2 ROP and 15 eyes had zone 2 ROP. There was a regression of ROP activity and good anatomical outcome in all but 6 eyes (4 infants). In these cases, it was done a second injection in 3 eyes (2 infants) but finally laser ablation of the avascular peripheral retina was done in all with good anatomical results. The refractive outcome was possible to achieved in 28 infants and it shows a tendency to myopia / high myopia in the infants who performed combined treatment and ametropia / low myopia in infants who had intravitreal injections of anti-VEDF drug as a primary treatment. Anti-VEGF strategy in ROP is effective and is changing the rational of ROP treatment. However, there is a long way until a complete understanding of the effects, limits, complications and follow-up of the infants who received this treatment.



Susana Teixeira
Lisbon, Portugal
Email :
Cell Phone: +351917630432
Work Phone: +351917630432